Laurus Labs Limited vs Pfizer Limited
A side-by-side comparison of Laurus Labs Limited (LAURUSLABS) and Pfizer Limited (PFIZER) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.
On the numbers, Pfizer Limited leads LAURUSLABS vs PFIZER on 10 of 14 metrics. See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).
- Valuation04
- Profitability04
- Growth11
- Size & financial health31
Each axis shows this group's split of that metric, scaled so the leader sits at the edge. Relative to each other, not an absolute score.
Valuation
PFIZER takes 4/4How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.
Profitability
PFIZER takes 4/4How efficiently each company turns capital and sales into profit. Higher is better.
Growth
EvenThree-year compounded growth. Faster-growing businesses can justify a higher valuation.
Size & financial health
LAURUSLABS takes 3/4Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.
- + []
- − ["Stock is trading at 21.00 times its book value", "The company has delivered a poor sales growth of 7.2% over past five years.", "The company has delivered a poor profit growth of -2.0% over past five years."]
- + ["Company has been maintaining a healthy dividend payout of 47.5%", "Company is almost debt free."]
- − ["The company has delivered a poor sales growth of 2.4% over past five years."]
This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.